ENABLE Platform for Clinical Trials in Mood Disorders Collecting Biomarker Data in Depression and Bipolar Disorder for Ages 16 and Older

What this Trial Is About

Mood disorders, including depression and bipolar disorder, affect over 350 million people worldwide. Matching the right treatment to each individual is challenging and can lead to prolonged illness and reduced quality of life. This research aims to advance the search for biomarkersclinical tests, blood tests, or imagingthat can help diagnose and treat mood disorders by creating a large, standardized study platform called ENABLE. The ENABLE platform provides standardized methods to collect detailed clinical and neurobiological data from individuals aged 16 and older with mood disorder symptoms. Participants complete clinical assessments and may opt for additional tests such as blood samples, MRI and EEG scans, cognitive tasks, and wearing an activity monitor for two weeks. The platform also serves as a recruitment pool for future biomarker-based clinical trials and offers open-source data for research purposes. Participants will undergo tiered assessments, with tier 1 including required clinical interviews and questionnaires, and tier 2 offering optional neuroimaging, blood collection, cognitive testing, and actigraphy. Researchers will measure participation rates and collect data to support biomarker discovery. The study involves ongoing data collection and follow-up until March 2029, providing a resource for future clinical trials and scientific analyses.

An Innovative Master Platform for Clinical Trials in Mood Disorders